Clearmind Medicine enters clinical trial agreement with Johns Hopkins

Clearmind Medicine has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine, to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder. The CM-CMND-001 clinical trial is a multinational, multi-center, single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects. Clearmind’s flagship treatment is focused on AUD, which is an extremely common and devastating condition. The addiction varies from mild to acute and describes a person’s inability to control their alcohol consumption, despite negative health, social and occupational consequences. In the clinical trial, oral capsules will be administered once daily for ten consecutive days. The patients will report their drinking patterns and craving for alcohol during the clinical trial period. Patients will also be monitored for their depression symptoms. Johns Hopkins University School of Medicine is the second US-based medical site to join the Company’s clinical trial. The first US-based site was Yale School of Medicine’s Department of Psychiatry.